A number of carbapenem antibiotics, for example imipenem, panipenem and meropenem are currently in clinical use due to their broad antibacterial spectra and potent bactericidal effects.1) However, a number of problems still remain with these agents, in particular, activity against resistant Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and the Gram-negative pathogen Pseudomonas aeruginosa, is relatively weak. Furthermore, stability to the renal enzyme dehydropeptidase-I (DHP-I) is poor, especially for the first generation examples imipenem and panipenem, but is also not exceptionally good for meropenem, the prototypical second generation carbapenem. As a part of our research for novel carbapenems possessing potent broad spectrum antibacterial efficacy and good DHP-I stability, we earlier described a novel series of 2-alkoxymethylpyrrolidin-4-ylthio derivatives 2 and reported the biological profile, including in vivo efficacy.2) These compounds possessed good DHP-I stability, high urinary recovery, and good activity against P. aeruginosa, however activity against MRSA was not sufficient.
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